42.05
-0.59%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Orient Europharma Co
Its shares trade on Taipei Exchange under the ticker 4120.TWO. It has been listed since 28 November 2002. In the fiscal year to 31 December 2025, it reported revenue of TWD 4.60bn and a net loss of TWD 567.4m. At that date it held total assets of TWD 12.21bn and shareholders' equity of TWD 6.29bn.
Orient Europharma Co. Ltd. is engaged in the manufacturing and trading of western medicine, health food and cosmetics. The company is headquartered in Taipei City, Taipei. The company went IPO on 2002-11-28. The firm operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Nov 2002
- Website
- oepgroup.com ↗
Leadership
Pay as last reported
- Mr. Jing Hong TsaiChairman of the Board, since 1982
- Mr. Mon Lin TsaiGeneral Manager, Director, since 2005
- Ms. Jiaxiu LinGeneral Manager-Greater China Area Nutrition & Health Business
- Mr. Jinzeng LuGeneral Manager-Western Medicine Brand Development & New Business Division
- Mr. Jianming TanGeneral Manager-Southeast Asia Area Nutrition & Health Business
- Pinjie WangHead of Finance & Accounting
- Shufen LinDirector
- Mr. Wende WangDirector
- Mr. Junjie WuDirector
- Mr. Huaming LinIndependent Director
- Dr. Praveen TyleIndependent Director
- Ms. Anita ChenHead of Corporate Public Affairs, since 2017
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Orient Europharma manufactures infant milk powders and functional healthcare products in Taipei City.
- The company provides dermatological preparations and medical hair care series for the Health Care sector.
- Orient Europharma offers cardiovascular disease treatments and cancer medications in the Pharmaceuticals industry.
Weaknesses
- Orient Europharma's western drugs segment lacks products for respiratory diseases beyond asthma.
- The company's health food segment does not include dietary supplements for elderly consumers.
- Orient Europharma's cosmetics line does not feature anti-aging products for mature skin.
Opportunities
- Orient Europharma can expand its medical cosmetic products in the growing Asian market.
- The company can leverage its infant milk powder segment to enter the Chinese market.
- Orient Europharma may increase its cardiovascular disease product line to meet rising demand.
Threats
- Orient Europharma faces competition from local manufacturers in the Taipei City market.
- The company's medical cosmetic products segment is vulnerable to changing consumer preferences.
- Orient Europharma's western drugs segment could be affected by new regulations in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.